{"title":"Beyond phenylalanine control in maternal phenylketonuria: reframing protein and amino acid requirements.","authors":"Jessica N Strosahl, Amber Malik, Rani H Singh","doi":"10.1097/MCO.0000000000001266","DOIUrl":"https://doi.org/10.1097/MCO.0000000000001266","url":null,"abstract":"<p><strong>Purpose of review: </strong>Maternal phenylketonuria (PKU) management has appropriately centered on restricting dietary phenylalanine (Phe) to prevent fetal toxicity. This review argues that the next advance should be to define what must be provided: trimester-appropriate total protein, a complete essential amino acid pattern, controlled but not deficient Phe, and sustained tyrosine availability.</p><p><strong>Recent findings: </strong>Direct studies in healthy pregnancy suggest that protein requirements rise from approximately 1.22 g/kg/day in early gestation to 1.52 g/kg/day in late gestation, while requirements for individual amino acids do not increase uniformly. These findings challenge fixed protein prescriptions in maternal PKU, where a substantial proportion of protein may be delivered as rapidly absorbed free amino acids, and current guideline adjustments of 20-40% above reference protein intakes remain consensus based. Recent maternal PKU reports suggest that Phe tolerance cannot be predicted reliably from gestational stage or fetal genotype, and the increasing availability of Phe-lowering therapies heightens concerns about Phe insufficiency. Fixed daily tyrosine targets likewise do not address diurnal fluctuation and the need for sustained availability.</p><p><strong>Summary: </strong>Maternal PKU nutrition should move beyond Phe restriction alone toward precision provision of protein and amino acids across gestation, with attention to quantity, quality, source, timing, and utilization to optimize maternal and fetal health.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sarcopenic obesity: definition, pathophysiology, and intervention strategies.","authors":"Christelle Guillet, Audrey Embry, Alexandre Pinel, Yves Boirie","doi":"10.1097/MCO.0000000000001264","DOIUrl":"https://doi.org/10.1097/MCO.0000000000001264","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sarcopenic obesity (SO) is increasingly recognized as a clinically relevant condition associated with functional impairment, cardiometabolic complications, disability and mortality. However, its diagnosis remains challenging because of heterogeneous definitions, uncertain thresholds, and limited accessibility of body composition assessment in routine clinical practice. This review summarizes recent advances and remaining challenges in the characterization and management of SO.</p><p><strong>Recent findings: </strong>Recent studies have contributed to a better understanding of the epidemiology, clinical consequences and multifactorial pathophysiology of SO, highlighting the importance of muscle quality and the interplay between adipose tissue, skeletal muscle, immune, endocrine and metabolic pathways. Emerging approaches, including pragmatic functional screening tools, innovative phenotype index and artificial intelligence, may improve disease characterization and risk stratification, although further validation is needed. Multicomponent lifestyle interventions combining exercise and nutritional optimization remain the mainstay of management, while incretin-based therapies raise new questions regarding muscle preservation and weight cycling.</p><p><strong>Summary: </strong>SO remains a heterogeneous and incompletely characterized condition. Progress toward clinical implementation will require greater harmonization of diagnostic approaches, validation of emerging tools, and intervention trials assessing muscle-related and patient-centred outcomes.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Omega-3 fatty acids and human health: why strong claims remain on fragile consensus.","authors":"Priscila Giacomo Fassini, Serge Rezzi","doi":"10.1097/MCO.0000000000001224","DOIUrl":"10.1097/MCO.0000000000001224","url":null,"abstract":"<p><strong>Purpose of review: </strong>Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) consumption remains widespread despite inconsistent reported health benefits. This review discusses multiple issues related to the efficiency of ω-3 PUFAs on human health including factors driving ω-3 PUFAs bioavailability and growing concerns about product quality.</p><p><strong>Recent findings: </strong>Recent clinical research reports ω-3 PUFAs benefits in various areas including cardiometabolic health, inflammation, cognitive protection, pregnancy outcomes, cancer and certain neuropsychiatric conditions. However, effects on healthy individuals and dietary recommendations need stronger clinical evidence. Heterogeneity in supplementation response involves genetic variability, microbiome, oxidative stress, diet and differences in supplementation protocols. Moreover, some of ω-3 PUFAs products are prone to significant oxidative degradation which can drastically reduce health benefits while possibly being detrimental. Yet ω-3 PUFAs oxidation status of products remains rarely reported and the effects of long-term consumption of oxidized lipids in humans still need to be established.</p><p><strong>Summary: </strong>Future clinical practices and research should shift toward biomarker-guided and personalized ω-3 PUFAs intervention strategies with mandatory prerequisite knowledge about product quality, e.g. dietary supplements and ω-3 PUFAs rich/fortified foods, and baseline blood-based ω-3 PUFAs nutritional status. Standardized reporting of formulation, oxidation status, and participant baseline characteristics is essential to clarify dose-response relationships and optimize therapeutic efficacy of ω-3 PUFAs.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"538-543"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Iron deficiency during pregnancy and lactation.","authors":"Laura Wasserfallen, Diego Moretti","doi":"10.1097/MCO.0000000000001257","DOIUrl":"10.1097/MCO.0000000000001257","url":null,"abstract":"<p><strong>Purpose of review: </strong>Iron deficiency persists as the most common nutritional deficiency worldwide and is highly prevalent among women of reproductive age. Pregnancy substantially raises iron requirements, increasing the risk of complications for mother and newborn particularly in low-income and middle-income countries. We summarize current evidence on the determinants, physiological adaptations, diagnostic thresholds, and management of iron deficiency during pregnancy and lactation, focusing on recent developments.</p><p><strong>Recent findings: </strong>Maternal iron regulation during pregnancy involves progressive hepcidin suppression to enhance absorption and fetal iron transfer, though regulatory mechanisms remain incompletely understood. Daily supplementation may maintain maternal iron status more effectively than an alternate-day regimen but is associated with more side effects; thus, the choice of regimen should be individualized and based on context. Multiple micronutrient supplements offer superior clinical outcomes compared to iron-folic supplements. For moderate-to-severe iron deficiency or late-pregnancy correction, intravenous iron has proven to be well tolerated and highly effective.</p><p><strong>Summary: </strong>Effective management requires early identification using ferritin-based diagnostic thresholds. Intravenous iron is an essential clinical tool for rapid correction or when oral iron is poorly tolerated. Sustainably improving maternal iron status globally would prevent iron deficiency in pregnancy but further necessitates integrated public health approaches - addressing dietary quality, low-dose supplementation, sanitation, and digital health interventions.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"503-509"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Steven Brantlov, Christian Lodberg Hvas, Lars Jødal, Leigh C Ward
{"title":"Bioelectrical impedance analysis instruments: clarifying concepts and the importance of standardization: a comment on the article by Dupertuis et al .","authors":"Steven Brantlov, Christian Lodberg Hvas, Lars Jødal, Leigh C Ward","doi":"10.1097/MCO.0000000000001254","DOIUrl":"10.1097/MCO.0000000000001254","url":null,"abstract":"","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"533-535"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Choline and metabolic health, a missing link in a critical chain.","authors":"Evan M Paules","doi":"10.1097/MCO.0000000000001252","DOIUrl":"10.1097/MCO.0000000000001252","url":null,"abstract":"<p><strong>Purpose of review: </strong>Emerging evidence suggests that choline plays a significant role in mediating metabolic disease beyond the regulation of hepatic triglycerides. The aim of this article is to present a current, brief synthesis focused on the impact of choline intake on metabolic health and to identify future directions in this research space.</p><p><strong>Recent findings: </strong>Recent work has linked low choline intake to obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes, and obesity-associated cognitive decline. A new methodology now enables more precise discrimination of choline intake in clinical populations. Emerging evidence reframes circulating trimethylamine N-oxide (TMAO) as a marker of metabolic dysfunction driven by obesity and a high-fat diet, rather than a direct consequence of dietary choline intake. Preclinical and clinical studies further suggest that adequate choline intake may be protective against obesity-related disease progression, particularly when established early in life.</p><p><strong>Summary: </strong>Choline is emerging as an important mediator of metabolic health and disease progression. A deeper understanding of the mechanisms regulating choline metabolism is critical to tailor nutritional therapies and mitigate metabolic disease progression. The impact of new antiobesity medications, including GLP-1 receptor agonists, on choline requirements also warrants investigation.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"519-526"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beyond deficiency: micronutrients in the era of precision medicine: are we asking the right questions?","authors":"Karin Amrein, Manfred Eggersdorfer","doi":"10.1097/MCO.0000000000001256","DOIUrl":"https://doi.org/10.1097/MCO.0000000000001256","url":null,"abstract":"","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":"29 6","pages":"501-502"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christian Stoppe, Kursat Gundogan, Stefano Marelli
{"title":"Micronutrients in adult critically ill patients: lessons learned and the path toward precision.","authors":"Christian Stoppe, Kursat Gundogan, Stefano Marelli","doi":"10.1097/MCO.0000000000001253","DOIUrl":"10.1097/MCO.0000000000001253","url":null,"abstract":"<p><strong>Purpose of review: </strong>Despite strong biological plausibility, empiric high-dose micronutrient supplementation has failed to improve outcomes in critically ill patients. This review synthesizes evidence from the past 18 months and outlines the necessary transition toward biomarker-guided precision nutrition.</p><p><strong>Recent findings: </strong>Recent evidence has further challenged routine high-dose micronutrient therapy. High-dose intravenous vitamin C failed to improve outcomes and was associated with potential harm in patients with sepsis, COVID-19, severe burns, and post-cardiac arrest syndrome. In contrast, a 2025 meta-analysis reported reduced short-term mortality and shorter ICU stay with vitamin D supplementation in patients on mechanical ventilation. Thiamine may shorten the duration of shock without affecting mortality. Observational studies suggest that carnitine deficiency is common during critical illness, and both deficiency and excess may be associated with adverse outcomes in critically ill patients. Selenium supplementation continues to show no clinical benefits in multiple sepsis phenotypes and high-risk surgical populations. Novel evidence also links trace element dysregulation to critical illness-acquired weakness, implicating copper-dependent cuproptosis, zinc homeostasis, and iron metabolism in the pathogenesis of muscle dysfunction. Advances in biomarkers (e.g. hepcidin, soluble transferrin receptor, ferritin, and selenoprotein P) are enabling more accurate identification of true deficiency states and targeted replacement strategies.</p><p><strong>Summary: </strong>Current evidence does not support routine high-dose single-micronutrient therapy in critically ill patients and suggests potential harm with pharmacological doses of vitamin C. Clinicians should ensure that daily baseline requirements are met and reserve supplementation only for patients with biomarker-confirmed deficiency or biologically defined high-risk phenotypes. Future research should prioritize precision nutritional approaches based on validated biomarkers and individualized metabolic profiling.</p>","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"510-518"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Author's response to Brantlov, Lodberg Hvas, Jødal and Ward.","authors":"Yves Marc Dupertuis","doi":"10.1097/MCO.0000000000001255","DOIUrl":"https://doi.org/10.1097/MCO.0000000000001255","url":null,"abstract":"","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":"29 6","pages":"536-537"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}